Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte, a clinical-stage biotechnology company (Nasdaq: HUMA), announced participation in five scientific events in September 2021 to present data on their engineered off-the-shelf human acellular vessel (HAV). CEO Laura Niklason emphasized the potential of HAV in various applications, highlighted by presentations on long-term durability in dialysis and its use in vascular repair and pancreatic islet transplantation. The HAV has been used in over 460 implants and is undergoing two Phase 3 trials, showcasing its promise as a revolutionary treatment option.